African University of Science and Technology (AUST)’s Post

🌟 Presenting our first current cohort of startups! 🌟 Meet the startups from our EIT Health InnoStars Challenge-based Acceleration program powered by Roche Slovensko that are ready to offer innovative solutions to today's healthcare challenges. 1️⃣ Challenge: Advancing Breast Cancer Screening and Early Diagnostics 🔹 The Blue Box Biomedical Solutions Women lack reliable breast cancer (BC) screening methods, as 50% of BCs are detected in a late-stage. The Blue Box has developed a radiation-free, pain-free, low-cost device detecting BC in urine with 88.33%. This outperforms mammography by 15% across all age groups and by 30% for women under 50. 🔹 Glooma Glooma is developing a home and portable medical screening device, the SenseGlove, to detect and monitor changes in the breast tissue. Their goal is to empower women while doing the breast self-exam and to contribute to the early detection of breast cancer. 2️⃣ Challenge: Remote patient monitoring of MS patients 🔹 Mild Blue Mild Blues makes the work of healthcare professionals simpler, more convenient, more accurate, and faster by developing artificial intelligence algorithms and creating truly functional and useful digital solutions. 🔹 NeuroBlast The Neuroblast Ecosystem is designed to assist both adults and children with neurodegenerative diseases, enabling continuous exercise and remote monitoring of the patients during post-rehabilitation at home. 🔹 eSteps Health 🐜 Democratizing access to healthcare for frail patients through the journey to health with personalized remote digital biomarkers of mobility quality. These startups exemplify innovation and dedication, and we're proud to support their journey towards shaping the future of healthcare. They will be accompanied by CIVITTA coaches Martin Vesely, Jurga Mecinskiene Erik Ehasoo and Roche challenge owners Lucia Markusková Daša Slezáková and Natália Bobovnická Stay tuned for more updates on their progress and impact! Second part of cohort is coming soon. #Startups #StartupAccelerator #InnovationChallenge #RocheSlovensko #HealthcareInnovation  #Innovation #Civitta #eithealth

Why healthtech marketing is complicated, and specified from marketing? It is like "standard" marketing, right? These are typical questions, I meet regularly, and even though that they are quite valid, there are things we need to mention to see the full picture. If we really simplify it, marketing as a sales support engine, is a very complex set of rules and tools, which could be best friend and the worst time, money and energy consuming enemy of any companies. Majority of healthtech entrepreuners does not have the competence and experience in business fields, therefore marketing seems to be a necessary burden. At the beginning, then later thoughtful planning can bring expert to the team, who can tame the wild horse of commercialization, but unfortunately in many cases it remains in a cage with the huge sign „proceed with caution”. This is the first, and the most important environmental circumstance, which requires a special approach when we are talking both lecturing and using marketing, in health tech companies. The second and more time consuming, which even requires stronger internal competence is to select the efficient set of tools and channels, serving certain business needs and goals. This process starts with solid planning, lot of internal iterations and then a continous measurement and finetuning. Of course the journey starts with the proper education, and this field has a very special role in the accelerator programmes, I have the opportunity to manage or support. On March 13th, I will run a Healthtech Marketing training for the 9 great startups (https://lnkd.in/djMD5mqF), selected for EIT Health InnoStars and Roche challenge based programme. During the training I will focus on the following topics: 💡 Personas and messaging 💡 Strategy vs Plan 💡 Essentials of KPIs 💡 Funnels 💡 Healthcare Marketing 💡 Digital Marketing 💡 Analog Marketing 💡 Next Steps in the journey Based on my experience and last years' feedbacks, this is a great starting package for early stage startups to launch their journey and start to utilize the potential values of a carefully planned and executed marketing strategy.

Competition opens to elevate early-stage medtech pitches Medtech entrepreneurs are being invited to the Early-Stage Innovation Forum (ESIF), a unique platform for developers to pitch their innovation at the 2024 AusMedtech national conference in Adelaide. The ESIF rapid-fire pitch competition provides presenters with an opportunity to pitch their early-stage innovation to a panel of expert judges for feedback that will prepare them for their capital raising journey ahead. This exclusive opportunity offers early-stage projects and technologies in the areas of medical devices and diagnostics, digital health and enabling technologies, the chance to gather feedback essential for commercialising, from a panel of industry experts as well as corporate VCs and early-stage investors. During their seven-minute presentation, presenters will be required to outline the problem they are trying to address, their innovative approach to solving the problem, the technology’s competitive advantage, development plan and investment proposal. Companies that have advanced beyond seed funding are encouraged to express their interest in AusMedtechInvest 2024, Australia’s inaugural boutique medtech investment roundtable forum, and aims to build meaningful personal connections between innovative medical technology (devices and diagnostic) businesses and investors, and help great ideas attract the capital needed to thrive in a fast-paced, competitive market. Investors are also invited to apply for their complementary pass here. The #ESIF is run bi-annually and features presentations from Australia's local research institutes, universities, hospitals, and pre-series A companies. QIMR Berghofer’s A/Prof Michelle Hill, winner of Best Translational Research at the AusMedtech 2023 ESIF, said: “The feedback from the panel will help to further refine the pitch as I will be looking for investors for my startup to commercialise the discovered biomarkers to new blood tests for ovarian cancer diagnosis and early detection.” Submissions received by 12 April will be reviewed by the appointed Advisory Group and applicants will be contacted with further information once the evaluation process is complete. Click here to register your project or company to present at the ESIF, and read more about A/Prof Hill’s novel ovarian cancer diagnostic tool: https://lnkd.in/gXfymAMy Pictured: 2023 AusMedtech ESIF competition winner QIMR Berghofer Medical Research Institute A/Prof Michelle Hill, PhD.

In a month, two of our Project Leads, Greta Preatoni from MYNERVA and Waldemar Hoffmann from Liver4Life (aka Apersys AG) will head to Boston as part of Venturelab's Venture Leaders Medtech 2024 💫 During the one-week roadshow, the 10 Venture Leaders will meet investors in the USA and engage with executives and experts in the #Medtech industry. Excited to see how this week will transpire 😀 More info about the other Venture Leaders below 👇 #VLeadersMedtech #SwissStartups #MedtechInnovation #InnovationInHealth #SwitzerlandInnovation #FutureOfHealthcare

🌐 Transforming Healthcare with Innovative Technology 🚀 I'm thrilled to share insights from this compelling article on [Business Insider], highlighting the groundbreaking advancements in MRI scans by startup Ezra. As the CTO of Apex Consultants Inc this resonates deeply with our mission to revolutionize healthcare through cutting-edge technology. 🔗 [Link to Business Insider Article: "Pitch deck of Ezra, the startup using AI to improve MRI scans, which just raised $23 million in funding"](https://lnkd.in/ebm6bKFS) 💡 **Importance of Health Solutions:** The Ezra pitch deck underscores the transformative impact of technology on healthcare. At Apex Consultants Inc we are dedicated to leveraging these advancements to enhance patient care and outcomes. 💲 **Cost Reduction for Accessible Care:** Accessible healthcare is paramount, and cost reduction plays a pivotal role. By harnessing cutting-edge technology, we aim to drive down healthcare costs and increase affordability for patients. It's about leveraging innovation to make a tangible difference in people's lives. 🌿 **Embracing Natural Healing Processes:** Ezra's approach to MRI scans highlights the importance of blending technology with natural healing processes. Integrating alternative medicine into our solutions allows us to provide holistic care options that prioritize patient well-being. 🏥 **How Apex Consultants Inc Can Help:** At www.apex-consultant.com, we combine our expertise in technology and healthcare to develop innovative solutions that address today's healthcare challenges. By leveraging AI, data analytics, and our deep understanding of the healthcare landscape, we can create cutting-edge products that improve patient outcomes and enhance the overall healthcare experience. 📈 **Generating Better Healthcare Products:** Our collaboration with www.apex-consultant.com enables us to drive innovation and create healthcare products that elevate the standard of care. By continuously improving and refining our offerings, we strive to enhance the cure ratio and empower individuals to live healthier lives. 🤝 **Join the Movement:** Let's continue to push the boundaries of what's possible in healthcare. Together, we can harness the power of technology to revolutionize patient care, reduce costs, and improve outcomes. #HealthTech #InnovationInHealthcare #DigitalHealth #CTOInsights 💊🌐

Our company AIMedExpert is very excited to explore the connection between #MetabolicSyndrome and #CancerRisk with our advanced AI algorithms, contributing to the groundbreaking work of the MiWear Consortium. Metabolic Syndrome (#MetS)—a cluster of disorders including #obesity, #insulinresistance, #hypertension, and #dyslipidemia—not only elevates the risk of cardiovascular diseases but also shows a strong association with several cancers, such as endometrial, bladder, prostate, and colorectal cancers. At AIMedExpert, we're leveraging our cutting-edge AI tools to investigate these intricate relationships, uncover hidden insights, and ultimately drive innovations in #Healthcare. This AI-driven exploration promises to advance our understanding of how metabolic disorders influence cancer progression and outcomes, enabling earlier diagnosis and more targeted treatments. 🔗 Read more about MiWear and our role in tackling Metabolic Health Syndrome by reading the main post below. #CancerPrevention #AIinHealthcare #MetS #MetabolicHealth #Innovation #HealthTech #AIMedExpert #BigData #MiWear #PersonalizedMedicine #CancerResearch

Exciting progress in the fight against #lymphedema! Swiss-based Lymphatica Medtech has secured €17.9 million in Series B funding to accelerate the clinical development of #LymphoDrain, a pioneering implantable device for lymphedema treatment. Here’s why this is a big step forward: Game-Changing Innovation: LymphoDrain is the first device of its kind—minimally invasive and designed to actively replace the lymphatic draining function, offering a much-needed option for patients. Strong Investor Support: Major backers like Panakes Partners, TechWald Holding S.p.A., and CDP Venture Capital SGR are investing in the vision. It’s great to see investor confidence behind a technology that could transform lives. Expanding Reach: With a new subsidiary in #Italy, Lymphatica is scaling up R&D, manufacturing, and clinical operations to bring this technology to those who need it most. Experienced Leadership: Industry expert Dan Rose joins as Chairman, bringing valuable experience to guide Lymphatica's growth. Meeting a Huge Need: Lymphedema affects over 10 million people globally, and treatment options are limited. LymphoDrain has the potential to be a transformative solution for millions. “We are thrilled to have closed our Series B financing, which will enable us to advance the clinical development of our groundbreaking technology for lymphedema patients,” said Dr. Marco Pisano, CEO and co-founder of Lymphatica Medtech. “With the support of our investors and new board members, we are one step closer to delivering a transformative solution that will significantly improve the lives of those suffering from lymphedema.” Valentina Triacca, COO and co-founder of Lymphatica Medtech, added: “Millions of people live with chronic lymphedema, and current treatment options fall short of providing effective relief. This investment allows us to continue advancing our LymphoDrain device, which has already shown promising results in a pilot feasibility study.” Alessio Beverina, Managing Partner at Panakès said: “Lymphatica is addressing a massive unmet medical need, with over 10 million people affected by lymphedema. This technology has the potential to transform the lives of those patients.” Dr. Lukas GUENTHER, CIO of TechWald added: "With its technology, Lymphatica is well-positioned to bring true sustainable clinical innovation in the treatment of lymphedema, greatly benefiting patients, physicians, and healthcare systems in various countries around the world." #LymphedemaCare #MedTechInnovation #HealthTech #SeriesBFunding #PatientCare #HealthcareSolutions #dubai #Uae #Medtech #digital #Innovation

April was a whirlwind 🌪️...and May is sprinting along the same track! 😱 Can you believe it's already been a month since I bid farewell to the amazing 5th cohort of my DayOne Health 4.0 Accelerator ? We wrapped up the program in style at the BOOM Summit. 🎉 Each of the 15 startups has reason to celebrate their accomplishments over the past months! Here are some standout highlights - sorted alphabetically of course: 📍Avegen (🇬🇧) clinched an HSJ NHS Partnership award for the most effective contribution to Clinical Redesign for their groundbreaking HIV digital clinical pathway, Klick. They also secured selection for the UK Government's IDAP (Innovative Devices Access Pathway) for their solution tackling fatigue in MS patients. 📍Briya (🇮🇱) successfully closed their Series A at $11.5 million, propelling their expansion to the USA and Europe. The team also reached the Health tech pitch competition finals at the MWC / 4YFN in Barcelona. 📍CliniNote (🇵🇱) inked partnerships with Novartis Poland and IQVIA. The team also earned the runner-up spot at the BOOM Innovation Showcase. 📍InSilicoTrials (🇮🇹) is paving the way towards Good Simulation Practices (GSP) and published their book with the In Silico World consortium, incl. the FDA. Among other news, they closed their bridging round towards Series A and claimed 3rd place at the BOOM Innovation Showcase. 📍machineMD (🇨🇭), jointly with Oxford-based start-up gaitQ, received a million-dollar research grant from Innovate UK and Innosuisse to enable the collection and analysis of critical movement data from people with Parkinson’s (PwP).  📍Risklick (🇨🇭) launched their Protocol AI solution to optimize clinical trial protocols. On the same day, they announced the closing of their Seed round, with an investment from Debiopharm. 📍TrialHub (🇧🇬/🇬🇧) pitched in front of 1'000+ Pharma executives at Reuters Events Pharma in Barcelona and secured 2nd place in their Digital Health Startup Challenge. 👏 Hats off to these trailblazing entrepreneurs who dare to reshape clinical trials and boost patient outcomes! I will eagerly keep an eye on their progress and continue supporting them through our DayOne - Healthcare Innovation Alumni community. 🤩 Feeling inspired? Dive into how the DayOne Health 4.0 Accelerator supports health tech startups seeking to collaborate with Pharma. 🌐 More info & Application : https://lnkd.in/ecK_msU7 ⏰ Deadline: June 15, 2024 🚀 Ready to join the ranks of 15 startups revolutionizing "AI, Data and Digitally enhanced clinical development" in our next cohort? Apply now! Jamie Campbell, Neeraj Apte, Dr. Nayan Kalnad, Ruth Levi Lotan, Yossi Zarfati, Rami Jonatan Kahan, Robert Lugowski 🩺 📑, Rafal Szmuc, Jan Poleszczuk, Luca Emili, Mario Torchia, Dorina Stanculescu, MBA, Phil Norris 💡, Poorya Amini, Maya Zlatanova, Rali Vaskova #DayOneBasel #InnovateInBasel #DayOneAlumni #Cohort5 #AI #Data #ClinicalTrials #HealthTech #Startups

Great panel at LSI Dana point talking about the future of cardiac care!

👀 ▶️ ▶️ ▶️ Last week’s OBN Network event provided plenty of insights into the current MedTech landscape and whistle-stop tour of three very cool MedTech innovators. 🤓 Some key learnings: 🔍 Patent application growth is surging in MedTech, but so is the backlog in approvals, which may be slowing down product introductions and innovation cycles. Seshadri (Sesh) Thirumalai's presentation highlighted the need to address this bottleneck to sustain the industry’s growth momentum. 🔍  Alex Hay’s analysis of emerging go-to-market models revealed how startups are increasingly dominating deal value in MedTech. Startups aren’t just securing investment but also forming partnerships with established tech giants, amplifying their impact. The ideal strategy? Partner, Acquire, or Perish! 🔍 Nadja Ulrich from Syneos Health highlighted the critical commercial challenges MedTech companies face, emphasising the importance of early strategy, particularly in deeply understanding the unmet clinical need and for navigating complex regulatory environments. While MedTech is brimming with innovation, the industry still faces significant scaling and commercial challenges —challenges that the following founders seemed to be meeting head-on through their pioneering solutions: 🌱 Francesca Cordeiro, Founder of Novai, is leading the development of a groundbreaking retinal biomarker and AI technology to detect eye and neurodegenerative diseases at their earliest stages. This innovation has the potential to significantly improve patient outcomes through earlier, more precise detection. 🌱 Kam Pooni, CEO of Glyconics, is transforming chronic disease screening with their portable infrared spectroscopy technology. The device, which is compact and easy to use, offers high-accuracy, needle-free screening for COPD and diabetes and presents a massive opportunity to impact healthcare delivery through faster, sample-free point-of-care testing. 🌱 David Browning, Chief Strategy Officer at EarSwitch, is revolutionising medical monitoring with their innovative in-ear technology, offering racially inclusive oximetry. This tech breakthrough overcomes the limitations of traditional finger devices, which are affected by skin tone. I loved hearing from these founders and learning about their innovations. Thanks to OBN (UK) Ltd for a fascinating event. #LifeSciences #MedTech #DigitalTransformation #MakeBusinessSocial —------------- 😁 I'm Chris 🗣️ Partnering with life sciences companies to raise their profile, visibility and authority Liked this post? Want to see more? 🔔 Ring the bell on my profile 🚀 Follow me ➡️ Connect with me